The steroid 5-a reductase type 2 (SRD5A2) is critical for prostatic development and growth. Strategies to block SRD5A2 using 5-a reductase inhibitors (5ARI) remain a mainstay in the treatment of benign prostatic hyperplasia (BPH). However, one-third of men are resistant to 5ARI therapies. We previously have found that body mass index (BMI) can predict increased SRD5A2 promoter methylation level and decreased protein expression level. We have demonstrated that there is an androgenic to estrogenic switch when SRD5A2 is absent in the prostate gland. Here we wished to identify whether obesity-associated inflammation contributes to the androgenic to estrogenic switch in human prostate tissue.
INTRODUCTION AND OBJECTIVES:
The steroid 5-a reductase type 2 (SRD5A2) is critical for prostatic development and growth. Strategies to block SRD5A2 using 5-a reductase inhibitors (5ARI) remain a mainstay in the treatment of benign prostatic hyperplasia (BPH). However, one-third of men are resistant to 5ARI therapies. We previously have found that body mass index (BMI) can predict increased SRD5A2 promoter methylation level and decreased protein expression level. We have demonstrated that there is an androgenic to estrogenic switch when SRD5A2 is absent in the prostate gland. Here we wished to identify whether obesity-associated inflammation contributes to the androgenic to estrogenic switch in human prostate tissue.
METHODS: Human prostate tissue samples came from men undergoing transurethral prostate resection. Primary prostatic stromal cells were isolated from patients undergoing prostate reduction therapy for BPH. Adipocytes and macrophages were differentiated and treated with saturated fatty acids (SFA) to induce inflammation, and SFA-free conditioned media were collected for stromal cell culturing. Protein and mRNA were extracted from stromal cells, the expression of aromatase, estrogen receptor alpha (ERa), G-protein coupled estrogen receptor (GPER) and SRD5A2 was determined by Western Blot, ELISA and qPCR.
RESULTS: In BPH patients, BMI was significantly correlated with methylation of SRD5A2 gene promoter (p<0.05) and absence of SRD5A2 protein expression. Higher BMI was associated with higher SRD5A2 methylation levels and absence of SRD5A2 expression, as well as higher levels of aromatase and ERa (P<0.05, respectively). In primary cultured prostatic stromal cells, the levels of aromatase, ERa and GPER were significantly increased, the level of SRD5A2 was significantly decreased in a dose-dependent manner when cultured with conditioned media of adipocytes or macrophages. There were much higher levels of aromatase, ERa and GPER in the prostatic stromal cells when adipocytes and macrophages were pretreated with SFA. CONCLUSIONS: Our study demonstrates for the first time that there is an androgenic to estrogenic switch, which can improve SRD5A2 methylation level and reduce SRD5A2 expression in the prostate glands of overweight patients. Associated with body weight, somatic epigenetic silencing of SRD5A2 changes the prostatic hormonal milieu, and may modulate prostatic homeostasis and growth. Targeting the estrogenic signaling may serve as an effective treatment strategy in subset of overweight BPH patients. Central obesity is known to be involved in benign prostatic hyperplasia (BPH). Some study reports that increased fat tissue induces chronic intra-prostatic inflammation and the change of Estrogen Receptora(ERa) and ERb ratio which contributes to the development of BPH. We already confirmed that the high-fat-diet (HFD) induced obesity rats increased urinary frequency and the weight of prostate. Furthermore the ERa expression was significantly increased in the prostate of obesity rats. To find out the detailed mechanism of the ERs, the expression of the ERs and inflammatory cytokines in the prostate using a HFD induced obesity rat model were investigated.
METHODS: Male Wistar rats (8 weeks, n[16) were divided into four groups; normal diet group (ND, n[4), high fat diet group (HFD, n[4), high fat dietþERa antagonist (HFD-ERa antagonist, n[4), high fat dietþERb agonist (HFD-ERb agonist, n[4). The ND formula contained 5%fat, meanwhile the HFD contained 32% fat. The rats were maintained on these diets for 16 weeks. HFD-ERa antagonist and HFDERb agonist rats were administered since 12 week. ERa antagonist: MPP dihydrochloride 1mg/kg/day, ERb agonist: S-Equol 5mg/kg/day. We investigated the prostate weight, analysis of mRNA expression and histopathology of the prostate in each group.
RESULTS: In HFD, weight of the prostate and urinary frequency was significantly increased compared to ND. In addition, the mRNA expression of inflammatory cytokines (IL-1b, IL-6) were significantly increased. In HFD-ERa antagonist, weight of the prostate and urinary frequency was decreased compared to HFD. The mRNA expression of inflammatory cytokines were also significantly decreased compared to HFD. In Hematoxylin-Eosin stain and Masson Trichrome stain, inflammatory cells and collagen fibers were increased into prostatic stromal area in HFD, while ND and HFD-ERa antagonist did not demonstrate.
CONCLUSIONS: HFD intake induced prostatic enlargement and inflammation in associated with altered immune-balance and the expression of ERs. ERa antagonist could play the role of prevention to BPH associated with obesity.
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MP06-03 EFFECTS OF COX2 INHIBITION ON BLADDER OVERACTIVITY IN RAT MODEL OF CHEMICALLY INDUCED PROSTATIC INFLAMMATION
Shinsuke Mizoguchi*, Pittsburgh, PA; Kenichi Mori, Hiromitsu Mimata, Oita, Japan; Jianshu Ni, Masahiro Kurobe, Tetsuichi Saito, Donaldo B. DeFranco, Zhou Wang, Naoki Yoshimura, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: There is increasing evidence that prostatic inflammation contributes to lower urinary tract symptoms (LUTS) in male with benign prostatic hyperplasia (BPH) and that cyclooxygenase-2 (COX-2) expression is increased in BPH tissues from patients exhibiting significant inflammation. Therefore, to reveal the role of COX-2-dependent prostatic inflammation in bladder overactivity, we investigated bladder function and molecular expressions in the prostate and pelvic afferent pathways after prostatic inflammation as well as the effects of COX-2 inhibition on bladder overactivity using a rat model.
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